E7 TCR-T cells + Aldesleukin
Phase 2RecruitingDevelopment Stage
Cervical Cancer
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Mar 7, 2023 → Jan 1, 2027
About E7 TCR-T cells + Aldesleukin
E7 TCR-T cells + Aldesleukin is a phase 2 stage product being developed by Iovance Biotherapeutics for Cervical Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05686226. Target conditions include Cervical Cancer, Throat Cancer, Oropharynx Cancer.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancer were approved
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05639972 | Phase 1/2 | Recruiting |
| NCT05686226 | Phase 2 | Recruiting |
Competing Products
20 competing products in Cervical Cancer